The anti-apoptotic proteins, specifically BCL2, BCL2L1 (Bcl-xL), and MCL1, are often overexpressed in cancer (7) and are associated with resistance and disease progression in prostate cancer (8, 9). This evidence concerns the gene BCL2 and prostate carcinoma.